Prostate Cancer: Screening
The question
To ask the Secretary of State for Health and Social Care, whether he plans to continue to support the TRANSFORM prostate cancer screening trial.
Answered by Andrew Gwynne
Research is crucial in tackling cancer, and the Government is strongly committed to supporting research into cancer. The Department spends £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer being the largest area of spend, at over £121.8 million in 2022/23. The NIHR spends more on cancer than any other disease group, reflecting its high priority.
The TRANSFORM trial is an important example of prostate cancer research, as a £42 million screening trial which aims to find ways of detecting prostate cancer earlier. Prostate Cancer UK is leading the development of the trial, with the Government contributing £16 million through the NIHR. The TRANSFORM trial will also aim to address some of the inequalities that exist in prostate cancer diagnosis today, ensuring that at least 10% of the men who are invited to participate in the trial are black, to inform a targeted approach for earlier diagnosis.
The NIHR welcomes funding applications for research into any aspect of human health, including prostate cancer. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →